印度制药工业市场前景及投资研究报告-培训课件外文版2024.5仿制药

INDUSTRIES

&

MARKETSPharmaceuticalindustryinIndiaCHAPTER

01GlobaloverviewRevenueoftheworldwidepharmaceuticalmarketfrom2001to2022(inbillionU.S.dollars)Pharmaceuticalmarket:worldwiderevenue2001-20221,6001,4001,2001,0001,4821,4501,3121,2781,204.81,135.11,115.71,073.11,063.6993.8963.2

964.4888.2830.6799800726.4648.7601.2559.96004002000498427.6390.22001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

20223Description:Theglobalpharmaceuticalmarkethasexperiencedsignificantgrowthinrecentyears.For2022,thetotalglobalpharmaceuticalmarketwasestimatedat1.48trillionU.S.dollars.Thisisaonlyaslightincreasefrom2021whenthemarketwasvaluedat1.42trillionU.S.dollars.Thepharmaceuticalmarketplaysakeyroleinhowpeoplegetmedicationsandwhatpeoplepayformedication.However,somemarketsarebetterforpharmaceuticalcompaniesthanothers.

ReadmoreNote(s):WorldwideSource(s):IQVIAProjectedglobalpharmaceuticalsalesfor2026,byregion(inbillionU.S.dollars)Worldpharmaceuticalsalesbyregionforecast2026SalesinbillionU.S.dollars295NorthAmericaEuropeanUnionSoutheast&EastAsiaChina774267189170LatinAmericaEuropenon-EU(incl.UK)8274JapanIndiansubcontinentCIS5240342919AfricaMiddleEastOceania4Description:TotalpharmaceuticalsalesnumbersinNorthAmericaareprojectedtoamounttosome774billionU.S.dollarsin2026,makingittheregionalsubmarketwiththehighestglobalpharmasalesbyfar.ReadmoreNote(s):Worldwide;asofSeptember2026Source(s):AstraZeneca;IQVIAGlobalspendingonmedicinesin2010,2022,andaforecastfor2027(inbillionU.S.dollars)Globalspendingonmedicines2010-20272,5002,0001,5001,9171,4821,00050008872010*2022**2027***5Description:Globalspendingonmedicinecontinuestogrow.In2022,approximately1.48trillionU.S.dollarshadbeenspentonmedicines,upfromjust887billionU.S.dollarsin2010.Thatnumberisexpectedtoincreasetoover1.9trillionbytheyear2027.Spendingonmedicineshasincreasedeverywhereglobally.However,theUnitedStatestakestheleadintotalmedicinesspendinggloballyandisexpectedtoremainthetopcountryformedicinesspendingthrough2027.

ReadmoreNote(s):Worldwide;asofNovember2021Source(s):IQVIATotalglobalspendingonpharmaceuticalresearchanddevelopmentfrom2014to2028(inbillionU.S.dollars)TotalglobalpharmaceuticalR&Dspending2014-20283503002503022962892812722622492442111942001501005018517116115114502014201520162017201820192020202120222023*202420252026202720286Description:In2022,researchanddevelopmentspendinginthepharmaceuticalindustrytotaledsome244billionU.S.dollarsglobally.Forcomparison,R&Dexpenditurestotaled137billiondollarsin2012.PharmaceuticalR&Dincludesallstepsfromtheinitialresearchofdiseaseprocesses,thecompoundtestingoverpre-clinical,andallclinicaltrialstages.Atacertainpointintheprocess-mostlyduringthepre-clinicalphase-agovernmentalauthorityisinvolvedtooverview,regulate,andultimately[...]

ReadmoreNote(s):Worldwide;asofAugust2023;*Allvaluesareprojectedfrom2023on.ReadmoreSource(s):EvaluateLeadingglobalpharmaceuticalcompaniesbasedonpharmarevenuein2022(inbillionU.S.dollars)Topglobalpharmaceuticalcompaniesbasedonpharmarevenue2022RevenueinbillionU.S.dollars40

50010203060708090100PfizerAbbVie91.356.2Johnson&JohnsonNovartis50.250.149.6Merck&Co.Roche47.945.4Bristol-MyersSquibbAstraZenecaSanofi4340.438.3GlaxoSmithKline7Description:Thisstatisticdepictsthetopglobalpharmaceuticalcompaniesbasedonpharmaceuticalrevenuein2022.Inthatyear,SwisscorporationNovartisgeneratedsome50billionU.S.dollarsofpharmaceuticalrevenue.Pfizer,however,heldontothefirstplace,stillmostlyduetorecord-breakingCOVID-19vaccinesales.ReadmoreNote(s):WorldwideSource(s):PharmaBoardroom;PharmaceuticalExecutive;Varioussources(companydata)CHAPTER

02GeneraloverviewGovernmenthealthcareexpenditureasashareofGDPinIndiafromfinancialyear2014to2022,withanestimatefor2025IndiangovernmenthealthcareexpenditureasashareofGDPFY2014-20253.0%2.5%2.5%2.1%2.0%1.8%1.5%1.4%1.4%1.5%1.0%0.5%0.0%1.3%1.3%1.2%1.2%FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY20259Description:TheIndiangovernmentwasestimatedtospendovertwopercentofthecountry'sGDPonhealthcareinfinancialyear2022.Thiswasforecastedtoreachover2.5percentoftheGDPbyfinancialyear2025.Thissignificantincreasewaspredictedbasedonthelikelihoodofgreaterpenetrationofgovernmenthealthinsuranceinthecountry.ReadmoreNote(s):India;FY2014toFY2022Source(s):ecodb;IMF;IndiaBrandEquityFoundationSizeofthehealthcaremarketinIndiafrom2008to2020,withanestimatefor2022(inbillionU.S.dollars)SizeofthehealthcaresectorinIndia2008-20224003503002502001501003722801601101048173686052455002008200920102011201220142015201620172020202210Description:India'shealthcaresectorwasworthabout280billionU.S.dollarsin2020anditwasestimatedtoreachupto372billiondollarsby2022.Thecountry'shealthcaremarkethadbecomeoneofthelargestsectorsintermsofrevenueandemploymentandtheindustrywasgrowingatarapidpace.ReadmoreNote(s):India;2008to2020Source(s):ArancaResearch;Frost&Sullivan;Varioussources(LSIFinancialServices,Deloitte)Distributionofcurrenthealthexpenditure(CHE)inIndiainfinancialyear2020,byhealthcareprovidersShareofcurrenthealthexpenditureinIndiaFY2020,byhealthcareprovidersShareofhealthexpenditure0%5%10%15%20%25%30%Generalhospitals-privatePharmacies28.39%22.19%Generalhospitals-government16.37%Allotherambulatorycentersgovernment**Providersofpreventivecare6.02%5.67%Officesofgeneralmedicalpractitioners(privateclinics)Medicalanddiagnosticlaboratories4.23%3.83%3.52%2.87%1.98%1.72%0.85%0.74%ProvidersofpatienttransportationandemergencyrescueGovernmenthealthadministrationagenciesOtherhealthcareprovidersnotelsewhereclassifiedOtherhealthcarepractitionersgovernment*PrivatehealthinsuranceadministrationagenciesSpecializedhospitals-government11Description:Infiscalyear2020,amongvarioushealthcareproviders,theprivategeneralhospitalsaccountedforover28percenttothecurrenthealthexpenditureofIndia.Thiswasfollowedbypharmacieswithacontributionofover22percent.

ReadmoreNote(s):India;FY2020;*Expenditureonsubcenters/ANM(auxiliarynursemidwife),ASHA(AccreditedSocialHealthActivist),anganwadicenters,etc.**Expenditureonprimaryhealthcentersanddispensaries.

India'sfinancialyearbeginsinApril[...]ReadmoreSource(s):NationalHealthSystemsResourceCentreMarketvalueofbiotechnologyindustryinIndiain2023,withestimatesfor2025and2030(inbillionU.S.dollars)MarketvalueofbiotechnologyindustryinIndia2020-203035030025020030015015092.310050020232025*2030*12Description:Asof2023,theIndianbiotechnologyindustrywasvaluedatover92billionU.S.dollars.Theindustrywasexpectedtoreachamarketvalueof300billiondollarsby2030.Thegrowthoftheindustrywouldbedrivenbytheincreasingdemandforvaccinesandbiopharmaceuticalsinthedomesticandinternationalmarkets.ReadmoreNote(s):India;2023;*Estimates.ReadmoreSource(s):InvestIndiaMarketvalueofbiotechnologyindustryinIndiain2023,bysegment(inbillionU.S.dollars)MarketvalueofbiotechnologyindustryinIndia2023,bysegment70605040302010057.514.111.59.3Bio-pharmaceuticalsBio-industryBio-agricultureBioIT&BioServices13Description:Thebiopharmaceuticalsectorhadthehighestmarketvalueatabout58billionU.S.dollarsamongthevariousbiotechnologymarketsegmentsinIndiain2023.Thebiotechnologymarketwasvaluedatover92billiondollarsinthesameperiod.

ReadmoreNote(s):India;2023Source(s):InvestIndiaMarketvalueofbiopharmaceuticalindustryinIndiafrom2015to2022(inbillionU.S.dollars)MarketvalueofbiopharmaceuticalindustryinIndia2015-20226050403049.839.438362824.323.818.9201002015201620172018201920202021202214Description:In2022,thevalueofthebiopharmaceuticalsmarketinIndiawasworthabout50billionU.S.dollars.Themarkethasshownagradualincreasingtrendsince2015.Thebiopharmaceuticalmarketmanufacturespharmaceuticalproductsinbiologicalsourcessuchasbloodcomponentsandstemcells.ReadmoreNote(s):India;2015to2022Source(s):AssociationofBiotechnologyLedEnterprisesCHAPTER

03TradeValueofIndianpharmaceuticalexportsfromfinancialyear2012to2023(inbillionU.S.dollars)IndianpharmaceuticalexportvalueFY2012-2023302525.424.622.420.719.12017.316.916.814.914.51510512.610.10FY2012FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY202316Description:Indiaistheworld'slargestproviderofgenericdrugs,andinfinancialyear2023,thecountryexportedpharmaceuticalsworthover25billionU.S.dollars.Intermsofvolume,Indiandrugscomprisedof20percentoftheglobalgenericdrugexports,outofwhichNorthAmericahadthelargestshare.ReadmoreNote(s):India;FY2012toFY2023Source(s):DepartmentofCommerce(India);DepartmentofPharmaceuticals(India);IndiaBrandEquityFoundation;KPMG;VarioussourcesValueofdrugsandpharmaceuticalexportedfromIndiainfinancialyear2023,byleadingdestination(inbillionIndianrupees)DrugsandpharmaceuticalexportvalueIndiaFY2023,byleadingdestinationExportvalueinbillionIndianrupees0100200300400500600700UnitedStatesUnitedKingdomBrazil606.3452.0751.7447.6NetherlandsRussia46.1642.07GermanyPeople'sRepublicofChinaUnitedArabEmiratesItaly27.9427.4815.583.54HongKong17Description:Indiaexporteddrugsandpharmaceuticalsworthabout606billionIndianrupeesinfiscalyear2023totheUnitedStates,makingitthehighestvalueofexportsinthissector.UnitedKingdomcameinsecondatabout52billionrupeesthatyear.ReadmoreNote(s):Worldwide,India;FY2023;provisionalfigures.Source(s):DGCI&S;ReserveBankofIndiaDistributionofpharmaceuticalexportsfromIndiaasofApril2023,bysegmentShareofpharmaceuticalexportIndia2023,bysegmentAyushandherbals3.00%Surgicals2.16%Vaccines4.01%Bulkdrugsandintermediates18.03%Formulationsandbiologicals73.31%18Description:AsofApril2023,formulationandbiologicalshadthehighestshareatover73percentamongthepharmaceuticalsexportsfromIndia.Thiswasfollowedbybulkdrugsandintermediateswithashareofover18percent.

ReadmoreNote(s):India;April2023Source(s):InvestIndiaValueofIndia'smedicineandpharmaceuticalproductimportsfromfinancialyear1961to2022,withanestimatefor2023(inbillionIndianrupees)MedicineandpharmaceuticalproductimportvalueIndiaFY1961-2023600517.37500457.27444.294003002001000355.7353.3356.91332.11335.2316.61318.94297.36248.43191.4917.234.680.10.240.85FY1961

FY1971

FY1981

FY1991

FY2001

FY2011

FY2012

FY2013

FY2014

FY2015

FY2016

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022FY2023*19Description:Indiaimportedmedicinalandpharmaceuticalproductstothevalueofalmost357billionIndianrupeesasoffiscalyear2022.UpuntilSeptember2023,Indiawillimportmedicalandpharmaceuticalproductsofmorethan318billionIndianrupeesinfinancialyear2023.Despitesloweconomicgrowthinthepastyears,Indiastillmanagedtostayaworldleaderinthepharmaceuticalsectorasamajorproducerofgenericdrugsandvaccines.However,duetoeconomicconsiderations,thecountry[...]

ReadmoreNote(s):India;FY1961toFY2023;*ProvisionalvaluesuntilSeptember2023.India'sfinancialyearbeginsinAprilandendsinMarch.Forexample,FY2017startedinApril2016andendedinMarch2017.OneIndianrupeeisequalto0.011euros[...]

ReadmoreSource(s):DGCI&S(Kolkata);UnionBudget(India)CHAPTER

04KeyplayersLeadingpharmaceuticalanddrugcompaniesinIndiain2023,bymarketcapitalization(inbillionIndianrupees)LeadingpharmaceuticalanddrugcompaniesIndia2023,bymarketcapitalizationValueinbillionIndianrupees1,000

1,50005002,0002,5003,000SunPharmaCipla2,413.61830.19756.24741.08613.35511.54478.62431.37Dr.Reddy'sLaboratoriesDivisLaboratoriesApolloHospitalsTorrentPharmaZydusLifesciencesAbbottIndiaMaxHealthcareAlkemLaboratories410.72393.0421Description:AsofFebruary2023,SunPharma,anIndianmultinationalcompanyheadquarteredinMumbai,sawamarketcapitalizationvalueofover2.4trillionIndianrupees.CiplaandDr.Reddy'sLabsrankedsecondandthirdrespectivelyduringthesametimeperiod.ReadmoreNote(s):India;2023Source(s):Website()IncomeofSunPharmaceuticalIndustriesLimitedfromfinancialyear2010to2023(inbillionIndianrupees)SunPharma'sincomeFY2010-2023500450400350445.2395.76343.34334.74322.02300.91291.4530025020015010050279.4273.28166.33116.8884.9160.8342.120FY2010FY2011FY2012FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY202322Description:Infiscalyear2023,SunPharmaceuticalIndustriesgeneratedaconsolidatedincomeofover445billionIndianrupees.Thisstoodatover395billionrupeesinthepreviousyear.SunPharmaceuticalIndustriesisaIndianpharmaceuticalcompanythatsellsandmanufacturesformulationsandingredientsprimarilyacrossIndiaandtheUnitedStates.ReadmoreNote(s):India;FY2010toFY2023;consolidatedfigures.Source(s):SunPharmaRevenueofAurobindoPharmaLimitedfromfinancialyear2013to2023(inbillionIndianrupees)AurobindoPharma'srevenueFY2013-2023300250200247.75248.55234.55230.99195.64165150.9139.55150121.211008158.55500FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY202323Description:Infiscalyear2023,AurobindoPharmaLimitedgeneratedarevenueofover248billionIndianrupees.Thiswasasignificantincreasecomparedtothepreviousyear,indicatingainclineingrowthforthecompany.

ReadmoreNote(s):India;FY2013toFY2023Source(s):AurobindoPharmaRevenueofDr.Reddy'sLaboratoriesLimitedfromfinancialyear2014to2023(inbillionIndianrupees)Dr.Reddy'sLaboratories'revenueFY2014-2023300250200150100245.88214.39189.72174.6154.71153.85148.19140.81142.03132.17500FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY202324Description:Dr.Reddy'sLaboratoriesearnedarevenueofabout245billionIndianrupeesinfinancialyear2023,markingasignificantrecoveryfromabout190billionrupeesworthrevenueinfiscalyear2021.Dr.Reddy'sisoneofthebiggestIndianmultinationalpharmaceuticalcompaniesbasedinthesoutherncityofHyderabad.ReadmoreNote(s):India;FY2014toFY2023Source(s):Dr.Reddy'sLaboratoriesIncomefromoperationsofCiplaLimitedfromfinancialyear2014to2023(inbillionIndianrupees)Cipla'sincomefromoperationsFY2014-2023250200227.53217.63191.6171.32163.62152.19146.315010050137.9113.45101.730FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY202325Description:Ciplaearnedaround227billionIndianrupeesasincomefromoperationsinthefiscalyear2023.Thiswasabigriseinincomecomparedtothepreviousyearwhenthecompanyearnedaround217billionrupees.

ReadmoreNote(s):India;FY2014toFY2023;consolidatedSource(s):CiplaCHAPTER

05ConsumerbehaviorRiseinmedicinepriceacrossIndiaasofApril2023HikeinmedicinepricesinIndia2023Shareofrespondents0%5%10%15%20%19%25%30%Pricesformostarehigherbyzeroto20percentPricesaremoreorlessthesame27%26%Pricesformostarehigherby20to50percentPricesformostarehigherbyover50percent12%Can'tsayasIpersonallydon'tpurchaseorhaven'tpaidattentiontopriceCan'tsayexactlyasIhavechangedmysource(wholesale,online,etc.)Pricesformostarelowerbyover20percent10%4%1%1%Pricesformostarelowerbyzeroto20percent27Description:AccordingtoasurveyconductedinApril2023,27percentofrespondentsstatedthatpricesformostmedicineshasincreasedbetweenzeroand20percentinIndia.Incomparison,12percentofrespondentsreportedthatthemedicinepriceshavehikedbyover50percent.ReadmoreNote(s):India;April1,2023;8,478respondents;across323districtsinIndiaSource(s):LocalCirclesReasonsforexcessunusedmedicinesacrossIndiaasofJune2023ReasonsforexcessunusedmedicinesinIndia202360%50%50%40%30%20%10%0%29%18%14%7%ChemistssellahigherminimumquantitythanwhatisneededWestoptakingtheprescribedmedicineafterafewePharmaciessellahigherminimumquantitythanwhatisneededDoctorsprescribemorethannecessaryOtherreasonsdays/gettingbetter28Description:AccordingtoasurveyaboutmedicinewastageconductedinJune2023,themajorityofrespondentsstatedthatchemistsellahigherminimumquantitythanwhatisneeded,whichhasresultedinmedicinewastageamongIndianhouseholds.Bycontrast,14percentofrespondentssaidthatdoctorsprescribemoremedicinethannecessary.ReadmoreNote(s):India;June13,2023;11,895respondents;across322districtsinIndiaSource(s):LocalCirclesOpiniononunusedmedicinesacrossIndiaasofJune2023OpiniononunusedmedicinesinIndia202350%43%45%40%35%30%25%20%15%10%5%27%22%6%2%0%ConsumersshouldbepermittedtoreturnanyChemistsandePharmaciesChemists,ePharmacies,andOthersolutionsareneededCan'tsayshouldberequiredtosell

pharmaceuticalmanufacturersunusedorsealedmedicine

medicinesinsmallerquantitiesshouldworkasbefore&insteadeverydistrictshouldquantitieswithinamonthwithwithpharmaceuticalpharmaceuticalmanufacturers

manufacturersalsomandated

haveahospitalwherepeoplealsomandatedtotakereturns

totakereturnsfromthem

candonateunusedmedicinesfromthem29Description:AccordingtoasurveyconductedonmedicinewastageinJune2023,43percentofrespondentsagreedthattheyshouldbepermittedtoreturnanyunusedorsealedmedicinequantitieswithinamonthalongwithamandatefrompharmaceuticalmanufacturerstotakereturnsfromconsumersinIndia.Bycontrast,sixpercento